Company profile
Neurelis, Inc.
Privately held: no public share price (Privately-held San Diego specialty pharma company (Valtoco diazepam nasal spray); explicitly described in its own press materials as privately-held, most recently closing a $114M Series D. Checked roster: no match. Sources: https://clinicaltrials.gov/study/NCT02721069 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://www.neurelis.com/neurelis-announces-close-114-million-series-d-financing-round-advance-neuroscience-focus/ Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Diazepam (Valtoco)(Valtoco) | Approved | GABA-A receptorSmall molecule | Epilepsy |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.